| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | CEO | Director
2 companies
Traversa Sergio is a Chief Executive Officer at RELMADA THERAPEUTICS, INC. with holdings across 2 companies. Recent SEC Form 4 filings include 15 buys and 11 sells.
Estimated insider holdings value: $9.5M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 15, 2025 | RLMD Relmada Therapeutics, Inc. | Chief Executive Officer | Buy | 27,500 | $4.12 | $113,300.00 | +2.2% | +41.7% | - | |
| Nov 5, 2025 | RLMD Relmada Therapeutics, Inc. | Chief Executive Officer | Buy | 272,500 | $2.20 | $599,500.00 | +27.3% | +51.4% | - | |
| Aug 28, 2025 | RLMD Relmada Therapeutics, Inc. | Chief Executive Officer | Buy | 265,976 | $0.67 | $178,094.99 | +10.7% | +440.6% | - | |
| May 20, 2025 | RLMD Relmada Therapeutics, Inc. | Chief Executive Officer | Buy | 350,000 | $0.50 | $174,712.71 | +22.9% | +11.2% | - | |
| Sep 11, 2024 | RLMD Relmada Therapeutics, Inc. | Chief Executive Officer | Buy | 140,000 | $2.82 | $395,114.52 | +16.0% | -84.4% | -49.7% | |
| Jan 31, 2024 | RLMD Relmada Therapeutics, Inc. | Chief Executive Officer | Buy | 100,000 | $3.87 | $386,737.56 | +18.7% | -7.4% | -91.0% | |
| Dec 8, 2022 | RLMD Relmada Therapeutics, Inc. | Chief Executive Officer | Buy | 55,250 | $2.10 | $115,804.00 | +62.2% | +51.6% | +18.0% | |
| Jul 1, 2022 | RLMD Relmada Therapeutics, Inc. | Chief Executive Officer | Sale+OE | 29,767 | $18.80 | $559,577.24 | -5.9% | +97.8% | -86.6% | |
| Mar 10, 2021 | RLMD Relmada Therapeutics, Inc. | CEO | Sale+OE | 10,000 | $35.48 | $354,844.92 | -3.5% | -13.8% | -35.7% | |
| Feb 24, 2021 | RLMD Relmada Therapeutics, Inc. | CEO | Sale+OE | 10,000 | $34.24 | $342,392.06 | -3.5% | - | - |